PMID- 31484548
OWN - NLM
STAT- MEDLINE
DCOM- 20200813
LR  - 20231013
IS  - 2051-1426 (Electronic)
IS  - 2051-1426 (Linking)
VI  - 7
IP  - 1
DP  - 2019 Sep 4
TI  - Biomaterial-based platforms for in situ dendritic cell programming and their use 
      in antitumor immunotherapy.
PG  - 238
LID - 10.1186/s40425-019-0716-8 [doi]
LID - 238
AB  - Dendritic cells (DCs) are central players in the immune system, with an exquisite 
      capacity to initiate and modulate immune responses. These functional 
      characteristics have led to intense research on the development of DC-based 
      immunotherapies, particularly for oncologic diseases. During recent decades, 
      DC-based vaccines have generated very promising results in animal studies, and 
      more than 300 clinical assays have demonstrated the safety profile of this 
      approach. However, clinical data are inconsistent, and clear evidence of 
      meaningful efficacy is still lacking. One of the reasons for this lack of 
      evidence is the limited functional abilities of the used ex vivo-differentiated 
      DCs. Therefore, alternative approaches for targeting and modulating endogenous DC 
      subpopulations have emerged as an attractive concept. Here, we sought to revise 
      the evolution of several strategies for the in situ mobilization and modulation 
      of DCs. The first approaches using chemokine-secreting irradiated tumor cells are 
      addressed, and special attention is given to the cutting-edge injectable 
      bioengineered platforms, programmed to release chemoattractants, tumor antigens 
      and DC maturating agents. Finally, we discuss how our increasing knowledge of DC 
      biology, the use of neoantigens and their combination with immune checkpoint 
      inhibitors can leverage the refinement of these polymeric vaccines to boost their 
      antitumor efficacy.
FAU - Calmeiro, Joao
AU  - Calmeiro J
AD  - Faculty of Pharmacy, University of Coimbra, 3000-548, Coimbra, Portugal.
AD  - Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504, 
      Coimbra, Portugal.
FAU - Carrascal, Mylene
AU  - Carrascal M
AD  - Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504, 
      Coimbra, Portugal.
AD  - Tecnimede Group, Sintra, Portugal.
FAU - Gomes, Celia
AU  - Gomes C
AD  - Coimbra Institute for Clinical and Biomedical Research, Faculty of Medicine, 
      University of Coimbra, Coimbra, Portugal.
AD  - Center for Innovation in Biomedicine and Biotechnology, University of Coimbra, 
      Coimbra, Portugal.
FAU - Falcao, Amilcar
AU  - Falcao A
AD  - Faculty of Pharmacy, University of Coimbra, 3000-548, Coimbra, Portugal.
AD  - Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), 
      University of Coimbra, Coimbra, Portugal.
FAU - Cruz, Maria Teresa
AU  - Cruz MT
AD  - Faculty of Pharmacy, University of Coimbra, 3000-548, Coimbra, Portugal.
AD  - Center for Neuroscience and Cell Biology, University of Coimbra, 3004-504, 
      Coimbra, Portugal.
FAU - Neves, Bruno Miguel
AU  - Neves BM
AUID- ORCID: 0000-0001-7391-3124
AD  - Department of Medical Sciences and Institute of Biomedicine - iBiMED, University 
      of Aveiro, Agra do Crasto - Edificio 30, 3810-193, Aveiro, Portugal. 
      bruno.neves@ua.pt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190904
PL  - England
TA  - J Immunother Cancer
JT  - Journal for immunotherapy of cancer
JID - 101620585
RN  - 0 (Biocompatible Materials)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Biocompatible Materials/administration & dosage/*chemistry
MH  - Cancer Vaccines/*immunology
MH  - *Cellular Reprogramming
MH  - Dendritic Cells/*immunology
MH  - *Drug Delivery Systems
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Neoplasms/immunology/*therapy
PMC - PMC6727507
OTO - NOTNLM
OT  - Antitumor immunotherapy
OT  - Biomaterial-based scaffolds
OT  - Dendritic cells
OT  - In situ mobilization
COIS- The authors declare that they have no competing interests.
EDAT- 2019/09/06 06:00
MHDA- 2020/08/14 06:00
PMCR- 2019/09/04
CRDT- 2019/09/06 06:00
PHST- 2018/10/24 00:00 [received]
PHST- 2019/08/23 00:00 [accepted]
PHST- 2019/09/06 06:00 [entrez]
PHST- 2019/09/06 06:00 [pubmed]
PHST- 2020/08/14 06:00 [medline]
PHST- 2019/09/04 00:00 [pmc-release]
AID - 10.1186/s40425-019-0716-8 [pii]
AID - 716 [pii]
AID - 10.1186/s40425-019-0716-8 [doi]
PST - epublish
SO  - J Immunother Cancer. 2019 Sep 4;7(1):238. doi: 10.1186/s40425-019-0716-8.